AZ-LIMELIGHT
24.3.2020 13:32:11 CET | Business Wire | Press release
Now developers can easily deploy their code across Limelight’s global edge platform with EdgeFunctions , a new distributed serverless computing capability. After extensive development and completion of its alpha testing program, Limelight Networks, Inc. (Nasdaq: LLNW) today announced that EdgeFunctions is in field trials with several customers with planned general availability in Q2.
With serverless architecture, developers don’t have to worry about the underlying infrastructure such as provisioning and managing servers or runtimes which can be costly and time consuming. Instead, they’re able to concentrate on writing and deploying code to create or enhance user application experiences.
EdgeFunctions allows developers to run their code in Limelight edge locations, taking advantage of Limelight’s global footprint and scale. Functions are globally available and run in the same locations as Limelight’s Content Delivery Network (CDN) -- closest to where content requests are received -- which ensures the lowest possible latency for code execution and delivers optimal user experiences. An API-first approach to serverless computing with support for Node.js, Python and Go frees developers to focus on innovation and integration with their content workflows.
EdgeFunctions targets the requirements of Limelight’s content delivery customers. It’s ideally suited to streaming video and content delivery use cases such as personalized streaming, access control, dynamic ad insertion, content protection, A/B testing, and image manipulation. EdgeFunctions is integrated with Limelight’s edge services platform, one of the world’s highest-performance streaming video and object delivery networks.
“Limelight's pivot to supporting the edge cloud with solutions such as EdgeFunctions will help differentiate the company's offerings and drive further growth. At IDC, we believe that Limelight's private CDN network coupled with the move toward stronger edge presence will help the company capitalize on increasing demand for live and on-demand video, key drivers of future CDN traffic growth,” said Ghassan Abdo, IDC Research Vice President, WW Telecom, Virtualization, Cloud and CDN.
“EdgeFunctions enables our customers to deploy their own application functions into our network edge locations and run them on demand,” said Nigel Burmeister, Global Marketing and Product Vice President at Limelight. “Developers can concentrate on delivering innovation and business outcomes without worrying about the underlying infrastructure. EdgeFunctions eliminates costly delays in latency-sensitive video and CDN workflows and dynamically allocates resources to scale as demand changes.”
About Limelight:
Limelight Networks, Inc. (NASDAQ: LLNW) is a global leader in delivering the highest quality online video experiences and edge-enabled workflows. Limelight has successfully helped launch and grow the largest video properties in the world and is on the forefront of enabling a new generation of applications that will disrupt markets and change our world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200324005160/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom